The November issue of Transplantation Direct covers a wide spectrum of topics in transplantation. Included in this issue are two kidney transplant studies from the UK looking at the impact of clinical nonattendance on outcomes, and at the actual value of referral center repatriation. We have a comprehensive review on the critical medical aspects of thrombosis related to end-stage liver disease, and publish a basic science comparative experimental study on single versus dual vessel perfusion methods associated with subnormothermic liver machine perfusion. For lung transplant specialists, we have a report on whether re-lung transplantation is advisable, and present a diagnostic method to assess unilateral chronic lung allograft dysfunction. In other areas of transplantation we offer a report on the value of heart transplantation in terms of recovering muscle mass and strength in patients with chronic heart failure, and for the islet transplant devotees we received an interesting letter reporting on mortality in Australia related to patients with type 1 diabetes and severe hypoglycemia, depending on whether they received an islet transplant, or not. We appreciate your interest in the journal and look forward to an article contribution from you soon.
REMINDER: Abstract Deadline is December 3, 2018
The TTS-ILTS Paired Transplant Centers Program is a collaboration between The Transplantation Society (TTS) and the International Liver Transplantation Society (ILTS) supporting new liver transplant programs in emerging countries.
TTS-ILTS program advertisement and question request: Please submit any questions you have about the program or the application process to firstname.lastname@example.org.
This Guide collates the most up to date information to provide transplant professionals with a comprehensive overview of the most recent advances in the field as well as technical guidance to ensure the quality and safety of human organs to be transplanted into patients. It contains information and guidance for all professionals involved in in identifying possible organ donors, co-ordinators managing the process of donation after death and that of living donation, professionals responsible for the allocation and clinical use of human organs, quality managers of the donation and transplantation process and Health Authorities responsible for the oversight of donation and transplantation programmes. Click on teh image above to access the download page.
Submitted by Dr Andrea Schlegel, Editorial Fellow, Transplantation.
Legendre C, Viebahn R, Fehrman-Ekholm I, et al.
The 5th Standalone Transplantation Meeting 2017, held in Nice, France was not only a satellite meeting at 2 additional locations in Sweden and Spain, participants at each location had the opportunity to exchange their knowledge and experience on long term challenges in transplantation of all solid organs. This paper is an excellent summary of key points, addressed by various experts in this field during the meeting. Current long-term issues after transplantation of all solid organs were presented and discussed including: ethical points of deceased and life donation, outcomes after transplantation of all solid organs and long-term complications in the context of immunosuppression. Two Important questions discussed were: First, how to safely minimize immunosuppression comparing all types of transplanted organs, and second, the development of malignancies and how to adjust immunosuppression accordingly. In addition, experts analysed current data on the development of diabetes and nephrotoxicity in the context of different immunosuppressive regimen.
Overall, this is a perfect read for all physicians, currently involved in solid organ transplantation, for younger colleagues to gain a lot of specific information and for experts an update at all ends.
November 14 - Glybera is a made-in-Canada discovery that made history, becoming the world's first drug approved to treat a genetic disease. But when it went on the market at a price of $1 million, it was immediately labelled the most expensive drug in the world and was only sold once.
November 6 - Mount Sinai researchers have developed a novel type of immunotherapy based on innovative nanotechnology that induces long-term organ transplant acceptance in mice. Their study, published in the November 6 online issue of Immunity, could transform patient care and help to overcome barriers that prevent successful long-term transplant outcomes.
November 5 - The research group of Thomas Johann Seebeck Department of Electronics of Tallinn University of Technology (TalTech) received a patent for the invention of superfast impedance spectroscopy measurement technology (1000 spectra per second). The newest invention of TalTech electronics engineers can be applied to monitor recovery of limbs with transplanted tissues, to analyse and diagnose the state of the nervous system of newborns and infants by lumbar puncture (collection of cerebrospinal fluid), and hopefully, to continuously monitor the state of liver transplants and other transplanted organs.
November 6 - Richmond-based United Network for Organ Sharing, commonly called UNOS, will continue to manage the nation's organ transplant system after successfully winning a new federal contract. UNOS operates the Organ Procurement and Transplantation Network through a contract with the Health Resources and Services Administration of the U.S. Department of Health and Human Services.
Novermber 13 - A study published yesterday in Advanced Materials provides details of the first fully personalized tissue implant, engineered from a patient's own materials and cells. The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.
November 13 - Venezuela is currently undergoing one of the worst economic crises in its history, resulting in hyper-inflation and severe food and medical supply shortages. This crisis has had a profound impact on the country's healthcare system: Generalized scarcity of basic medication and crumbling public hospital infrastructure are just some of the symptoms of what has become a public health crisis.
November 13 - The last three decades have seen the development of a procedure that enables blood group incompatible, or ABOi, organ transplants, including the kidney.